![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Renal cell carcinoma is a hot topic in urologic oncology, thanks to a better understanding of the disease mechanisms, which has resulted in the developments and approval of targeted therapies. Six agents are now approved in the treatment of metastatic renal cell carcinoma. Some new information was presented at the recent Joint 15th European Cancer Organisation (ECCO) – 34th European Society of Medical Oncology (ESMO) Multidisciplinary Congress in Berlin. This article highlights the most important presentations at this meeting.
Financial & competing interests disclosure
Ziya Kirkali is a speaker and Advisory Board member for Bayer Schering Pharma, and a Advisory Board member for Astra Zeneca. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.